KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma Meeting Abstract
| Authors: | Tabernero, J.; Bang, Y.; Van Cutsem, E.; Fuchs, C.; Janjigian, Y.; Bhagia, P.; Li, K.; Adelberg, D.; Qin, S. |
| Abstract Title: | KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma |
| Meeting Title: | ESMO 22nd World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Jul 1-4 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-07-01 |
| Start Page: | S101 |
| End Page: | S102 |
| Language: | English |
| ACCESSION: | WOS:000558722000039 |
| DOI: | 10.1016/j.annonc.2020.04.120 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-38 -- Source: Wos |
